• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    LAVA Therapeutics N.V. - Ordinary Shares (NQ:LVTX)

    1.495 -0.025 (-1.64%)
    Streaming Delayed Price Updated: 2:12 PM EDT, Oct 17, 2025 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 1,392,518
    Open 1.490
    Bid (Size) 1.490 (96)
    Ask (Size) 1.500 (12)
    Prev. Close 1.520
    Today's Range 1.440 - 1.520
    52wk Range 0.8502 - 2.093
    Shares Outstanding 26,289,087
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    XOMA Royalty and LAVA Therapeutics Announce Amendment to Purchase Agreement
    From XOMA Royalty Corporation; LAVA Therapeutics N.V.
    Via GlobeNewswire
    Thursday's after hours session: top gainers and losers
    Let's have a look at what is happening on the US markets after the closing bell on Thursday. Below you can find the top gainers and losers in today's after hours session. 
    Via Chartmill

    Performance

    YTD
    +45.1%
    +45.1%
    1 Month
    -1.0%
    -1.0%
    3 Month
    +6.8%
    +6.8%
    6 Month
    +14.1%
    +14.1%
    1 Year
    -9.4%
    -9.4%

    More News

    Read More
    XOMA Royalty Extends Tender Offer to Acquire LAVA Therapeutics N.V.
    From XOMA Royalty Corporation; LAVA Therapeutics
    Via GlobeNewswire
    LAVA Therapeutics Stock Slips 9% Pre-Market – Here’s Why The Company Canceled Its Shareholder Meeting
    Via Stocktwits
    4 Biotech Stocks That Are Showing Weakness: Momentum Scores Fading Over The Past Week
    Via Benzinga
    This Block Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday
    Via Benzinga
    BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: HilleVax, Inc. (Nasdaq – HLVX), Steelcase Inc. (NYSE – SCS), LAVA Therapeutics N.V. (Nasdaq – LVTX), Arcadia Biosciences, Inc. (Nasdaq – RKDA)
    From Brodsky & Smith LLC
    Via GlobeNewswire
    LVTX Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Lava Therapeutics N.V. Is Fair to Shareholders
    From Halper Sadeh LLC
    Via Business Wire
    XOMA Royalty Enters into Agreement to Acquire LAVA Therapeutics for Between $1.16 and $1.24 Per Share in Cash, Plus a Contingent Value Right
    From XOMA Royalty Corporation; LAVA Therapeutics N.V.
    Via GlobeNewswire
    Analyst Downgrades LAVA Therapeutics, Sees Pipeline Overhang
    Via Benzinga
    This Constellation Brands Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Thursday
    Via Benzinga
    On Wednesday, there are stocks with unusual volume. Let's take a look.
    Via Chartmill
    What's going on in today's session
    Via Chartmill
    Which stocks are experiencing notable movement on Tuesday?
    Via Chartmill
    Traders are paying attention to the gapping stocks in Tuesday's session.
    Via Chartmill
    LVTX Stock Earnings: LAVA Therapeutics Beats EPS for Q2 2024
    Via InvestorPlace
    LAVA Therapeutics to Participate in the H.C. Wainwright 2nd Annual Immune Cell Engager Virtual Conference
    From LAVA Therapeutics N.V.
    Via GlobeNewswire
    LAVA Announces Annual Meeting of Shareholders
    From LAVA Therapeutics N.V.
    Via GlobeNewswire
    LAVA Therapeutics to Participate in the Jefferies Global Healthcare Conference
    From LAVA Therapeutics N.V.
    Via GlobeNewswire
    LVTX Stock Earnings: LAVA Therapeutics Beats EPS, Misses Revenue for Q1 2024
    Via InvestorPlace
    LAVA Provides Business Updates and Reports First Quarter 2024 Financial Results
    From LAVA Therapeutics N.V.
    Via GlobeNewswire
    LAVA Therapeutics to Participate in the Citizens JMP Life Sciences Conference
    From LAVA Therapeutics N.V.
    Via GlobeNewswire
    LVTX Stock Earnings: LAVA Therapeutics Misses EPS, Misses Revenue for Q4 2023
    Via InvestorPlace
    LAVA Provides Business Updates and Reports Fourth Quarter and Year-End Financial Results
    From LAVA Therapeutics N.V.
    Via GlobeNewswire
    Increasing Incidence of Pancreatic Cancer Leading to a $6.85 Billion Dollar Market Size for New Treatments
    Via FinancialNewsMedia

    Frequently Asked Questions

    Is LAVA Therapeutics N.V. - Ordinary Shares publicly traded?
    Yes, LAVA Therapeutics N.V. - Ordinary Shares is publicly traded.
    What exchange does LAVA Therapeutics N.V. - Ordinary Shares trade on?
    LAVA Therapeutics N.V. - Ordinary Shares trades on the Nasdaq Stock Market
    What is the ticker symbol for LAVA Therapeutics N.V. - Ordinary Shares?
    The ticker symbol for LAVA Therapeutics N.V. - Ordinary Shares is LVTX on the Nasdaq Stock Market
    What is the current price of LAVA Therapeutics N.V. - Ordinary Shares?
    The current price of LAVA Therapeutics N.V. - Ordinary Shares is 1.495
    When was LAVA Therapeutics N.V. - Ordinary Shares last traded?
    The last trade of LAVA Therapeutics N.V. - Ordinary Shares was at 10/17/25 02:12 PM ET
    What is the market capitalization of LAVA Therapeutics N.V. - Ordinary Shares?
    The market capitalization of LAVA Therapeutics N.V. - Ordinary Shares is 39.30M
    How many shares of LAVA Therapeutics N.V. - Ordinary Shares are outstanding?
    LAVA Therapeutics N.V. - Ordinary Shares has 39M shares outstanding.
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.